灭活新冠疫苗安全性与免疫原性:两项随机临床试验中期分析
该中期分析评估了一种研究性灭活全病毒新冠疫苗在中国健康成人中的安全性和免疫原性。1期试验96人分3个剂量组及铝佐剂对照组,2期试验224人分两种免疫程序组及对照组。结果显示不良反应轻微且自限,无严重不良反应,疫苗组可检测到中和抗体,铝佐剂对照组无抗体应答。
要点
- 灭活新冠疫苗不良反应率低,以注射部位疼痛和发热为主,均轻微自限。
- 全程接种后14天,疫苗组中和抗体几何平均滴度可检测到,对照组无应答。
- 研究为1/2期中期分析,疗效和长期安全性需3期试验评估。
核心结论
- 该灭活新冠疫苗在1/2期试验中不良反应率低,并显示出免疫原性,研究仍在进行中。
- 疗效和更长期的不良事件评估将需要3期试验。
研究设计与样本
- 研究为正在进行的随机、双盲、安慰剂对照的1期和2期临床试验的中期分析。
- 试验在中国河南省开展,纳入18至59岁健康成人,1期96人,2期224人。
- 1期试验分3个剂量组(2.5、5、10 μg/剂)和氢氧化铝佐剂对照组,每组24人,于第0、28、56天肌肉注射3剂。
- 2期试验将224名成人随机分配至5 μg/剂的两个免疫程序组:第0和14天接种(疫苗组84人,佐剂对照组28人)及第0和21天接种(疫苗组84人,佐剂对照组28人)。
- 主要安全性结局为每次注射后7天内的合并不良反应,主要免疫原性结局为全程接种后14天针对活SARS-CoV-2的50%蚀斑减少中和试验中和抗体应答。
主要发现
- 1期试验中,铝佐剂对照组、低剂量组、中剂量组和高剂量组7天不良反应发生率分别为12.5%、20.8%、16.7%和25.0%。
- 2期试验中,第0和14天接种的疫苗组与佐剂对照组7天不良反应发生率分别为6.0%和14.3%;第0和21天接种的疫苗组与佐剂对照组分别为19.0%和17.9%。
- 最常见不良反应为注射部位疼痛,其次为发热,均轻微且自限,未观察到严重不良反应。
- 1期试验中,低、中、高剂量组第3剂后14天中和抗体几何平均滴度分别为316(95% CI,218-457)、206(95% CI,123-343)和297(95% CI,208-424)。
- 2期试验中,第0和14天及第0和21天接种疫苗者第2剂后14天中和抗体几何平均滴度分别为121(95% CI,95-154)和247(95% CI,176-345);所有铝佐剂对照组均未检测到抗体应答。
临床怎么用
- 该中期分析提示灭活新冠疫苗在健康成人中安全性良好且可诱导中和抗体,但疗效和长期安全性需等待3期试验结果。
局限性
- 本文为1/2期试验的中期分析,样本量有限,尚未评估疫苗 efficacy 和长期不良事件。
- 研究纳入18至59岁健康成人,未涵盖儿童、老年人及合并基础疾病人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: A vaccine against coronavirus disease 2019 (COVID-19) is urgently needed. OBJECTIVE: To evaluate the safety and immunogenicity of an investigational inactivated whole-virus COVID-19 vaccine in China. INTERVENTIONS: In the phase 1 trial, 96 participants were assigned to 1 of the 3 dose groups (2.5, 5, and 10 μg/dose) and an aluminum hydroxide (alum) adjuvant-only group (n = 24 in each group), and received 3 intramuscular injections at days 0, 28, and 56. In the phase 2 trial, 224 adults were randomized to 5 μg/dose in 2 schedule groups (injections on days 0 and 14 [n = 84] vs alum only [n = 28], and days 0 and 21 [n = 84] vs alum only [n = 28]). DESIGN, SETTING, AND PARTICIPANTS: Interim analysis of ongoing randomized, double-blind, placebo-controlled, phase 1 and 2 clinical trials to assess an inactivated COVID-19 vaccine. The trials were conducted in Henan Province, China, among 96 (phase 1) and 224 (phase 2) healthy adults aged between 18 and 59 years. Study enrollment began on April 12, 2020. The interim analysis was conducted on June 16, 2020, and updated on July 27, 2020. MAIN OUTCOMES AND MEASURES: The primary safety outcome was the combined adverse reactions 7 days after each injection, and the primary immunogenicity outcome was neutralizing antibody response 14 days after the whole-course vaccination, which was measured by a 50% plaque reduction neutralization test against live severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). RESULTS: Among 320 patients who were randomized (mean age, 42.8 years; 200 women [62.5%]), all completed the trial up to 28 days after the whole-course vaccination. The 7-day adverse reactions occurred in 3 (12.5%), 5 (20.8%), 4 (16.7%), and 6 (25.0%) patients in the alum only, low-dose, medium-dose, and high-dose groups, respectively, in the phase 1 trial; and in 5 (6.0%) and 4 (14.3%) patients who received injections on days 0 and 14 for vaccine and alum only, and 16 (19.0%) and 5 (17.9%) patients who received injections on days 0 and 21 for vaccine and alum only, respectively, in the phase 2 trial. The most common adverse reaction was injection site pain, followed by fever, which were mild and self-limiting; no serious adverse reactions were noted. The geometric mean titers of neutralizing antibodies in the low-, medium-, and high-dose groups at day 14 after 3 injections were 316 (95% CI, 218-457), 206 (95% CI, 123-343), and 297 (95% CI, 208-424), respectively, in the phase 1 trial, and were 121 (95% CI, 95-154) and 247 (95% CI, 176-345) at day 14 after 2 injections in participants receiving vaccine on days 0 and 14 and on days 0 and 21, respectively, in the phase 2 trial. There were no detectable antibody responses in all alum-only groups. CONCLUSIONS AND RELEVANCE: In this interim report of the phase 1 and phase 2 trials of an inactivated COVID-19 vaccine, patients had a low rate of adverse reactions and demonstrated immunogenicity; the study is ongoing. Efficacy and longer-term adverse event assessment will require phase 3 trials. TRIAL REGISTRATION: Chinese Clinical Trial Registry Identifier: ChiCTR2000031809.
引用
- Xia S, Duan K, Zhang Y, et al. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA. 2020. PMID: 32789505. doi:10.1001/jama.2020.15543
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。